In a filing, Pyxis Oncology Inc revealed its CFO & COO Connealy Pamela Ann acquired Company’s shares for reported $0.17 million on Nov 26 ’24. In the deal valued at $1.96 per share,88,850 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 1,199,143 shares worth roughly $2.13 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
William Blair downgraded its Pyxis Oncology Inc [PYXS] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Stifel began covering PYXS with “Buy” recommendation on August 08, 2024.
Price Performance Review of PYXS
On Monday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock jump 6.59% to $1.78. Over the last five days, the stock has lost -11.00%. Pyxis Oncology Inc shares have fallen nearly -1.11% since the year began. Nevertheless, the stocks have fallen -14.42% over the past one year. While a 52-week high of $6.85 was reached on 02/27/24, a 52-week low of $1.64 was recorded on 12/06/24. SMA at 50 days reached $3.2831, while 200 days put it at $3.8896.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 1.7267, which if violated will result in even more drops to 1.6733. On the upside, there is a resistance level at 1.8267. A further resistance level may holdings at 1.8733. The Relative Strength Index (RSI) on the 14-day chart is 28.62, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.4483, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.11%. Stochastics %K at 2.25% indicates the stock is a buying.
How much short interest is there in Pyxis Oncology Inc?
A steep rise in short interest was recorded in Pyxis Oncology Inc stocks on 2024-11-15, growing by 0.93 million shares to a total of 5.84 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.91 million shares. There was a rise of 15.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 09, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
